"Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used to lower plasma CHOLESTEROL levels.
| Descriptor ID |
D000924
|
| MeSH Number(s) |
D27.505.519.186.071.202 D27.505.954.557.500.202
|
| Concept/Terms |
Anticholesteremic Agents- Anticholesteremic Agents
- Agents, Anticholesteremic
- Inhibitors, Cholesterol
- Cholesterol Inhibitors
- Anticholesteremic Drugs
- Drugs, Anticholesteremic
- Anticholesteremics
|
Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticholesteremic Agents".
This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 6 | 2 | 8 |
| 2015 | 6 | 0 | 6 |
| 2016 | 4 | 2 | 6 |
| 2017 | 5 | 2 | 7 |
| 2018 | 2 | 2 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 5 | 2 | 7 |
| 2021 | 2 | 0 | 2 |
| 2022 | 5 | 0 | 5 |
| 2023 | 7 | 0 | 7 |
| 2024 | 4 | 2 | 6 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
-
Homozygous Familial Hypercholesterolemia Treatment: New Developments. Curr Atheroscler Rep. 2025 Jan 03; 27(1):22.
-
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2024 Dec 14; 404(10470):2462-2475.
-
Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025 Mar-Apr; 19(2):320-326.
-
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
-
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15; 31(3):302-310.
-
Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 Apr; 391:117472.
-
Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
-
Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment. Ann Med. 2023 12; 55(1):2199218.